Publications by authors named "Lev Verkh"

Claim this Profile
M
Mesenchymal stem cells in the treatment of severe COVID-19.
Santosh Kesari, Gregory C Kasper, Lev Verkh, Terese C Hammond, Marla L Matal

Transl Med Commun· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Mesenchymal stem cells in the treatment of severe COVID-19.
Santosh Kesari, Gregory C Kasper, Lev Verkh, Terese C Hammond, Marla L Matal

Transl Med Commun· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I/II Study of Safety and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Chronic Stroke.
Michael L Levy, John R Crawford, Nabil Dib, Lev Verkh, Nikolai Tankovich

Stroke· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale and design of a randomized controlled trial of allogeneic mesenchymal stem cells in patients with nonischemic cardiomyopathy.
Stephen J Greene, Stephen E Epstein, Raymond J Kim, Arshed A Quyyumi, Robert T Cole, Lev Verkh

J Cardiovasc Med (Hagerstown)· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer.
Fatima Cardoso, Jean-Luc Canon, Dino Amadori, Daniela Aldrighetti, Jean-Pascal Machiels, Lev Verkh

Breast· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer.
Jonas Bergh, Gabriella Mariani, Fatima Cardoso, Annelie Liljegren, Ahmad Awada, Lev Verkh

Breast· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study.
Francisco Robert, Alan Sandler, Joan H Schiller, Glenn Liu, Karen Harper, Lev Verkh

Cancer Chemother Pharmacol· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects.
Carlo L Bello, Laurie Sherman, Jihao Zhou, Lev Verkh, John Smeraglia

Anticancer Drugs· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of perflubron emulsion to decrease allogeneic blood transfusion in high-blood-loss non-cardiac surgery: results of a European phase 3 study.
Donat R Spahn, Klaus F Waschke, Thomas Standl, Johann Motsch, Léone Van Huynegem, Lev Verkh

Anesthesiology· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis